High-affinity TIGIT antibody and its applications
A high-affinity TIGIT antibody inhibits TIGIT-CD155 binding to enhance anti-cancer immune responses, addressing limited effectiveness and resistance in current therapies, effectively treating tumors with improved specificity and safety.
Patent Information
- Application Number
- JP2025538662
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-12-30
- Filing Date
- 2023-11-09
- Publication Date
- 2026-11-19
- Estimated Expiration
- 2043-11-09
AI Technical Summary
Current immune checkpoint therapies, such as PD-1/L1 and CTLA-4 blockers, have limited effectiveness in treating malignant tumors, with only 10-30% of patients showing a sustained response, and many develop secondary resistance, necessitating the development of antibodies targeting a wider range of immune checkpoints like TIGIT.
A high-affinity TIGIT antibody is developed to inhibit the binding of TIGIT to its ligand CD155, releasing immunosuppression and promoting anti-cancer immune cell function, with specific CDR sequences and humanized variants to enhance specificity and avoid secondary resistance.
The TIGIT antibody effectively suppresses tumor growth and metastasis, offering higher specificity and lower toxicity, with improved therapeutic outcomes for malignant tumors like lung, liver, and colon cancers.
Smart Images

Figure 0007954303000002 
Figure 0007954303000003 
Figure 0007954303000004
Abstract
Description
[Technical Field]
[0001] The present invention relates to the field of antibodies, more specifically to high-affinity TIGIT antibodies and their applications, and more specifically to antibodies or their antigen-binding fragments, nucleic acid molecules, expression vectors, methods for preparing antibodies or their antigen-binding fragments, recombinant cells, compositions and their uses, drugs and their uses, and methods for treating malignant tumors. [Background technology]
[0002] Malignant tumors are diseases that seriously threaten human life and health. Currently available treatments for malignant tumors include surgical resection, radiation therapy, chemotherapy, small molecule targeted therapy, immune checkpoint therapy, and cell and gene therapy. However, these have limited effectiveness in some patients with malignant tumors, and malignant tumors remain a formidable challenge for human life and health.
[0003] In recent years, immunotherapy has made remarkable progress in the field of oncology, with immune checkpoint blocking therapies, particularly those involving anti-CTLA-4 and anti-PD-1 or PD-L1 antibodies, attracting considerable attention. By blocking the binding of inhibitory receptors on the surface of T cells to their ligands, these therapies disrupt the transmission of inhibitory signals, correct immunosuppression mediated by the immunosuppressive microenvironment, and restore the antitumor capacity of T cells in the tumor microenvironment, resulting in high response rates in the treatment of various metastatic terminal malignancies (including metastatic melanoma, non-small cell lung cancer, and renal cancer). However, even though the overall response rate for PD-1 / L1 therapy, which currently has the broadest approved indications, is only 30%, it cannot be ignored that many patients are unable to benefit from it.
[0004] However, not all malignant tumor patients respond well to PD-1, PD-L1, or CTLA-4 blocking therapy. Only 10%–30% of patients show a long-term, sustained response to PD-1 or PD-L1 antibody treatment, with the vast majority showing insufficient response. On the other hand, because the expression of immune checkpoint ligands in tumors and tumor-infiltrating lymphocytes is relatively heterogeneous, a single type of immune checkpoint therapy cannot be applied to all patients, and many patients do not benefit from it. On the other hand, some patients who receive immune checkpoint therapy experience tumor recurrence and develop resistance to the therapy, resulting in secondary resistance, where continued administration does not yield therapeutic effects. For these two reasons, the development of immune checkpoint antibodies against a wider range of targets is necessary.
[0005] T cell immunoglobulin proteins and ITIM (Immunoreceptor tyrosine-based inhibitory motif) domain proteins (TIGIT) are important immune checkpoints, primarily expressed on the surface of spontaneously killing (NK) cells, activated CD8+ T and CD4+ T cells, regulatory T cells (Tregs), and follicular helper T cells (Tfh). The ligands recognized by TIGIT, CD155 and CD112, are primarily expressed in mononuclear cells, macrophages, dendritic cells (DCs), T cells, B cells, and many non-hematopoietic cells (including tumor cells of different histological types). The affinity of the TIGIT-binding ligand PVR (polivirus receptor, CD155) is significantly higher than that of its competing receptors, CD226 and CD96. TIGIT and its ligand binding transmit inhibitory signals via the intracellular ITIM motif, thereby suppressing the function of T cells and NK cells.
[0006] Studies have revealed a link between TIGIT expression and the development of various malignancies (e.g., non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, colorectal cancer, gliablastoma, gastric cancer, liver cancer, multiple myeloma, acute myeloid leukemia, and follicular lymphoma). Reports indicate that TIGIT molecules are highly expressed on the surface of tumor-infiltrating T cells in lung cancer patients, and there is a significant positive correlation between TIGIT expression and PD-1 expression. TIGIT expression on the surface of tumor-infiltrating NK cells in colon cancer patients is significantly higher than that on peripheral blood NK cells. In several mouse tumor models, blocking TIGIT with antibodies can suppress tumor growth and metastasis, and simultaneously, blocking both TIGIT and PD-1 can effectively treat tumors. Therefore, the development of therapeutic TIGIT antibodies is particularly necessary. [Overview of the Initiative] [Problems that the invention aims to solve]
[0007] The present invention aims to solve, at least to some extent, one of the technical problems in related technologies. [Means for solving the problem]
[0008] To suppress the problems of tumor growth, metastasis, and the resulting secondary resistance, the present invention provides a high-affinity TIGIT antibody and its application in the treatment of malignant tumors.
[0009] The antibody according to the present invention inhibits the binding of TIGIT to ligand CD155, thereby releasing TIGIT-mediated immunosuppression and promoting the anti-cancer function of immune cells.
[0010] Therefore, in order to achieve the above objective, in a first aspect of the present invention, the present invention proposes an antibody or an antigen-binding fragment thereof. According to an embodiment of the present invention, the antibody or the antigen-binding fragment thereof The heavy chain variable regions CDR1, CDR2, and CDR3 sequences are shown in amino acid sequences that are at least 80% identical to SEQ ID NO:1, 2, and 3, respectively, and Each of these sequences includes light chain variable regions CDR1, CDR2, and CDR3, which are represented by amino acid sequences that are at least 80% identical to SEQ ID NO: 4, 5, and 6 or 4, 5, and 6.
[0011] According to embodiments of the present invention, the antibody or its antigen-binding fragment binds to TIGIT, inhibits the binding of TIGIT to ligand CD155, releases TIGIT-mediated immunosuppression, activates the immune cell anti-cancer mechanism, and further suppresses tumor growth and proliferation. Furthermore, the antibody or its antigen-binding fragment has high specificity, which helps avoid the occurrence of secondary resistance problems.
[0012] According to embodiments of the present invention, the antibody or its antigen-binding fragment may further include at least one of the following additional technical features.
[0013] According to embodiments of the present invention, the antibody or its antigen-binding fragment is The sequence further includes the heavy chain variable region CDR1 sequence shown in SEQ ID NO:1, the heavy chain variable region CDR2 shown in SEQ ID NO:2, the heavy chain variable region CDR3 shown in SEQ ID NO:3, the light chain variable region CDR1 shown in SEQ ID NO:4, the light chain variable region CDR2 shown in SEQ ID NO:5, and the light chain variable region CDR3 shown in SEQ ID NO:6. GSSITSDYA (SEQ ID NO:1) ITYSGRT (SEQ ID NO:2), ARWGLLRRYFDY(SEQ ID NO:3) QDVFNQ (SEQ ID NO: 4) SASFRYT (SEQ ID NO: 5) QQHYSTPLT(SEQ ID NO:6).
[0014] According to embodiments of the present invention, the antibody or its antigen-binding fragment specifically recognizes TIGIT.
[0015] According to the examples of the present invention, said antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of said heavy chain variable region is set forth in SEQ ID NO:7, and the amino acid sequence of said light chain variable region is set forth in SEQ ID NO:8, QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGTLLTVSS(SEQ ID NO:7), DIVMTQSPSSMSTSVGDRVTITCRASQDVFNQVAWYQQKPGKSPKLLIYSASFRYTGVPDRFSGSGSGTDFTFTISSVQAEDFATYYCQQHYSTPLTFGAGTKLELK(SEQ ID NO:8).
[0016] According to the examples of the present invention, said antibody is a humanized antibody.
[0017] According to the examples of the present invention, said antibody or antigen-binding fragment thereof comprises a heavy chain framework region sequence and a light chain framework region sequence, and at least a part of at least one of said heavy chain framework region sequence and said light chain framework region sequence is derived from at least one of a mouse-derived antibody, a human-derived antibody, a primate-derived antibody, or a variant thereof.
[0018] According to the examples of the present invention, said antibody or antigen-binding fragment thereof comprises at least one of a heavy chain constant region and a light chain constant region, and at least a part of at least one of said heavy chain constant region and said light chain constant region is derived from at least one of a human-derived antibody, a primate-derived antibody, a mouse-derived antibody, or a variant thereof.
[0019] According to embodiments of the present invention, both the light chain constant region and the heavy chain constant region are derived from mouse-derived IgG1 antibody, IgG2a antibody or a variant thereof, or human-derived IgG1 antibody, IgG2 antibody, IgG3 antibody, IgG4 antibody or a variant thereof. According to embodiments of the present invention, the antibody or its antigen-binding fragment is at least one of single-chain antibody, multimeric antibody, CDR-transplant antibody, Fab antibody, and Fv antibody.
[0020] In a second aspect of the present invention, the present invention proposes a nucleic acid molecule. According to an embodiment of the present invention, the nucleic acid molecule encodes an antibody or an antigen-binding fragment described in the first aspect of the present invention.
[0021] Antibodies encoded by nucleic acid molecules or their antigen-binding fragments according to the embodiments of the present invention have stronger specificity, a longer half-life, and higher efficacy, effectively treating or preventing malignant tumors with lower doses, and exhibiting lower toxic side effects and greater safety.
[0022] In a third aspect of the present invention, the present invention proposes an expression vector. According to an embodiment of the present invention, the expression vector supports the nucleic acid molecule described in the second aspect of the present invention.
[0023] The expression vectors mentioned in the examples of the present invention can efficiently express the aforementioned antibodies or their antigen-binding fragments in appropriate receptor cells, and the antibodies or their antigen-binding fragments designed in the present invention have stronger specificity and higher safety.
[0024] In a fourth aspect of the present invention, the present invention proposes a method for preparing the above-mentioned antibody or antigen-binding fragment. According to an embodiment of the present invention, the method is The third aspect of the present invention involves introducing an expression vector into a cell, The process includes the step of culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or its antigen-binding fragment.
[0025] The inventors discovered that antibodies or antigen-binding fragments prepared according to the embodiments of the present invention can be cultured more efficiently than high-purity antibodies or antigen-binding fragments, and that the operating steps are simple and the cost is low.
[0026] According to an embodiment of the present invention, the cell is a eukaryotic cell.
[0027] In a fifth aspect of the present invention, the present invention proposes recombinant cells. According to an embodiment of the present invention, the recombinant cells express an antibody or antigen-binding fragment described in the first aspect of the present invention and carry a nucleic acid molecule described in the second aspect of the present invention or an expression vector described in the third aspect of the present invention.
[0028] According to some specific embodiments of the present invention, the recombinant cells can efficiently express antibodies or antigen-binding fragments in large quantities under appropriate conditions, and the antibodies or antigen-binding fragments have stronger specificity, a longer half-life and higher potency, allowing for the delivery of antibody drugs to target cells with smaller doses, effectively treating or preventing malignant tumors, and exhibiting lower toxic side effects and greater safety.
[0029] In a sixth aspect of the present invention, the present invention proposes a composition. According to an example of the present invention, the composition comprises an antibody or antigen-binding fragment described in the first aspect of the present invention, a nucleic acid molecule described in the second aspect of the present invention, an expression vector described in the third aspect of the present invention, or recombinant cells described in the fifth aspect of the present invention.
[0030] According to embodiments of the present invention, when introduced into a living organism, the composition of the present invention can achieve therapeutic effects similar to those of antibodies or their antigen-binding fragments, nucleic acid molecules, expression vectors, and recombinant cells.
[0031] In a seventh aspect of the present invention, the present invention proposes the use of a composition in the preparation of a drug. According to an embodiment of the present invention, the drug is used to treat or prevent malignant tumors.
[0032] According to embodiments of the present invention, the antibody or its antigen-binding fragment can be used to prepare a drug, the prepared drug having similar effects to the antibody or its antigen-binding fragment, and is used to treat or prevent diseases such as malignant tumors.
[0033] According to embodiments of the present invention, the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0034] In an eighth aspect of the present invention, the present invention proposes a drug. According to an example of the present invention, the drug comprises an antibody or antigen-binding fragment described in the first aspect of the present invention, a nucleic acid molecule described in the second aspect of the present invention, an expression vector described in the third aspect of the present invention, recombinant cells described in the fifth aspect of the present invention, or a composition described in the sixth aspect of the present invention, and is used to treat a malignant tumor.
[0035] The inventors discovered that drugs containing antibodies or their antigen-binding fragments, nucleic acid molecules, expression vectors, recombinant cells, or compositions have excellent therapeutic effects on the treatment and prognosis of malignant tumors.
[0036] According to embodiments of the present invention, the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0037] In a ninth aspect of the present invention, the present invention proposes the use of the aforementioned antibody or its antigen-binding fragment in the preparation of a kit. According to an example of the present invention, the kit is used to detect TIGIT.
[0038] According to embodiments of the present invention, the kit detects TIGIT more efficiently and accurately, saving time and exploration costs for clinical treatment.
[0039] In a tenth aspect of the present invention, the present invention proposes a kit. According to an example of the present invention, the kit comprises an antibody or antigen-binding fragment described in the first aspect of the present invention.
[0040] The inventors discovered that kits prepared based on antibodies or their antigen-binding fragments can be applied to scientific research, saving time and cost in the analysis of malignant tumors.
[0041] In an eleventh aspect of the present invention, the present invention proposes a method for treating or preventing malignant tumors. According to an embodiment of the present invention, the method comprises administering to a subject an antibody or antigen-binding fragment according to the first aspect of the present invention, a nucleic acid molecule according to the second aspect, an expression vector according to the third aspect, recombinant cells according to the fifth aspect, a composition according to the sixth aspect, or a drug according to the eighth aspect. The administration of an antibody or antigen-binding fragment according to any embodiment of the present invention, a nucleic acid molecule, an expression vector, recombinant cells, a composition, or a drug can be used to treat or prevent malignant tumors.
[0042] According to embodiments of the present application, the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0043] In a twelfth aspect of the present invention, the present invention proposes the use of an antibody or antigen-binding fragment described in the first aspect, a nucleic acid molecule described in the second aspect, an expression vector described in the third aspect, a recombinant cell described in the fifth aspect, a composition described in the sixth aspect, or a drug described in the eighth aspect in the treatment or prevention of malignant tumors. According to examples of the present invention, an antibody or antigen-binding fragment, a recombinant protein nucleic acid molecule, an expression vector, a recombinant cell, or a drug composition drug used in any example of the present invention can be used to treat or prevent malignant tumors.
[0044] According to embodiments of the present application, the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0045] Within the scope of the present invention, each of the above technical features of the present invention and each of the technical features specifically described below (means of implementation) can be combined with each other to form new or preferred technical means, and it should be understood that, due to space limitations, each one will not be repeated here. [Brief explanation of the drawing]
[0046] The above and / or additional aspects and advantages of the present invention will become apparent and easier to understand from the description of the embodiments combined with the following drawings.
[0047] [Figure 1] This figure shows the ELISA results of the TIGIT antibodies H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) according to Example 3 of the present invention binding to human and monkey TIGIT. [Figure 2] This figure shows the ELISA results demonstrating that the TIGIT antibody H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) according to Example 4 of the present invention inhibits the binding of TIGIT to CD155. [Figure 3] This figure shows the results of the binding of TIGIT antibodies H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) according to Example 5 of the present invention to 293T-TIGIT cells. [Figure 4] This figure shows the results of the TIGIT antibody H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) according to Example 6 of the present invention, which inhibits the binding of CD155-mIgG2a antibody to 293T-TIGIT cells. [Figure 5]This figure shows the results of the TIGIT antibody H401LV2-hlgG1LALA, according to Example 7 of the present invention, promoting IL-2 secretion from Jurkat T cells. [Figure 6] This figure shows the result of the TIGIT antibody H401LV2-mlgG2a binding to CHO-K1-TIGIT cells according to Example 8 of the present invention. [Figure 7] This figure shows the result of the TIGIT antibody H401LV2-mlgG2a, according to Example 9 of the present invention, inhibiting the binding of CD155 to CHO-K1-TIGIT cells. [Figure 8] This figure shows the results of the efficacy of the TIGIT antibody H401LV2-mIgG2a in the colorectal cancer MC38 model according to Example 10 of the present invention. [Figure 9] This figure shows the results of the drug efficacy of H401LV2-mIgG2aD265A in a lung cancer LLC model according to Example 10 of the present invention. [Modes for carrying out the invention]
[0048] The embodiments of the present invention shown in the drawings will be described in detail below. In all drawings, the same or similar reference numerals indicate the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the drawings are illustrative and for illustrative purposes only, and should not be understood as limitations on the present invention.
[0049] In the course of describing the present invention, interpretations of relevant terms in this specification have been made, but these interpretations and explanations are merely for the purpose of facilitating the understanding of the means and are not intended to be considered limitations on the means of protection of the present invention.
[0050] In this specification, the terms "include" or "include" are non-limiting, meaning they include the content described in this invention but do not exclude the content of other embodiments.
[0051] In this specification, the terms “optional,” “any,” or “optional” generally mean that the events or conditions described below may occur, but do not necessarily occur, and such descriptions include cases in which such events or conditions occur and cases in which such events or conditions do not occur.
[0052] To facilitate understanding of the present invention, certain technical and scientific terms are defined below. Unless otherwise explicitly defined herein, all other technical and scientific terms used herein have the meanings generally understood by those skilled in the art. Amino acid residue abbreviations refer to standard three-letter and / or one-letter codes indicating one of the 20 commonly used L-amino acids used in the art.
[0053] In the present invention, unless otherwise stated, the term antigen-binding fragment is used with respect to antibody fragment, which usually means an antigen-binding antibody fragment, which may contain a portion of a complete antibody, and is generally an antigen-binding region or variable region, and includes Fab, Fab', F(ab')2, Fv or scFv, biantibodies, linear antibodies, single-chain antibody molecules, etc.
[0054] The terms "complementary determinant region," "CDR," or "CDR sequence" refer to the amino acid sequence responsible for antigen binding in an antibody, typically the amino acid residues around 23-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable region, and around 31-35B (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)), and / or "high-variable loops" (e.g., amino acid residues around 26-32(LI), 50-52(L2) and 91-96(L3) in the light chain variable region, and around 26-32(H1), 53-55(H2) and 96-101(H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0055] On the premise that the antibody activity is not substantially affected (at least 95% activity is maintained), a person skilled in the art can substitute, add, and / or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more) amino acids from the sequences of the disclosure to obtain variants of the sequence of the antibody or its functional fragment. These are considered to fall within the scope protected by the disclosure. For example, an amino acid having similar properties in the variable region is substituted. The variant sequences described in the disclosure have at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similarity (or homology) with the reference sequence. The sequence similarity described in the disclosure can be measured using sequence analysis software, for example, the computer program BLAST, in particular BLASTP or TBLASTN, using default parameters. All amino acid sequences referred to in the disclosure are shown in an N-terminal to C-terminal manner.
[0056] In this specification, the terms “identity,” “homology,” or “similarity” refer to the determination of the proportion of the same amino acid or nucleotide between two amino acid or nucleic acid sequences in conventional methods when describing an amino acid sequence or nucleic acid sequence relative to a reference sequence, for example, Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York), and the ALIGN protocol (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research). See Foundation, Washington, DC. For measuring sequence alignment and sequence identity, there are many algorithms, including Needleman et al. (1970) J.Mol.Biol.48:443 homology alignment algorithm, Smith et al. (1981) Adv.Appl.Math.2:482 local homology algorithm, Pearson et al. (1988) Proc.Natl.Acad.Sci.85:2444 similarity search method, Smith-Waterman algorithm (Meth.Mol.Biol.70:173-187 (1997)), and BLASTP, BLASTN, and sumBLASTX algorithms (see Altschul et al. (1990) J.Mol.Biol.215:403-410).Computer programs utilizing these algorithms are also available, including but not limited to ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul et al., Meth. Enzym., 266:460-480 (1996)), or GAP, BESTFIT, BLAST Altschul et al., as well as FASTA and TFASTA, available in Genetics Computing Group (GCG) packages, version 8, Madison, Wisconsin, USA, and in CLUSTAL in PC / Gene programs provided by Intelligenetics, Mountain View, California.
[0057] As described above, the antibodies of the present invention may be full-length (e.g., IgG1 or IgG4 antibodies), may contain only an antigen-binding moiety (e.g., Fab, F(ab')2, or scFv fragment), or may be modified to affect their function. The present invention includes anti-TIGIT antibodies having a modified glycosylation mode. In some applications, modification is useful to remove undesirable glycosylation sites, or to enhance antibody-dependent cytotoxicity (ADCC) function, for example, by eliminating the iodine sugar moiety on the oligosaccharide chain. In some other applications, galactosylation modification is used to alter complement-dependent cytotoxicity (CDC).
[0058] As used in this text, the term "functional fragment" refers particularly to antibody fragments such as Fv, scFv (sc refers to a single chain), Fab, F(ab')2, Fab', scFv-Fc fragments or diaboantibodies, or any fragment whose half-life can be extended by chemical modification or liposome encapsulation, wherein the chemical modification is the addition of a poly(alkylene) glycol such as polyethylene glycol ("polyethylene glycolized, PEGylated") (referred to as polyethylene glycolized fragments of Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG, or Fab'-PEG) ("PEG" is polyethylene glycol), and the fragment has TIGIT binding activity. Preferably, the functional fragment consists of or contains a partial sequence of the heavy chain variable region or light chain variable region of its derived antibody, wherein the partial sequence is sufficient to maintain the same binding specificity and sufficient affinity as the derived antibody, preferably at least 1 / 100 of the TIGIT affinity of its derived antibody, and more preferably at least 1 / 10. Such a functional fragment comprises at least five amino acids, preferably the 10th, 15th, 25th, 50th, and 100th consecutive amino acids of the antibody sequence from which it is derived.
[0059] As described above, one aspect of the present invention proposes an antibody or an antigen-binding fragment thereof. According to an embodiment of the present invention, the antibody or the antigen-binding fragment thereof The heavy chain variable regions CDR1, CDR2, and CDR3 sequences are shown in amino acid sequences that are at least 80% identical to SEQ ID NO:1, 2, and 3, respectively, and Each of these sequences includes light chain variable regions CDR1, CDR2, and CDR3, which are represented by amino acid sequences that are at least 80% identical to SEQ ID NO: 4, 5, and 6 or 4, 5, and 6.
[0060] In a preferred embodiment of the present invention, the antibody may be humanized to further improve its bioacceptability; that is, the antibody is a chimeric antibody or a humanized antibody. The term "chimeric antibody" refers to a recombinant antibody obtained by using recombinant DNA technology to replace the constant region amino acid sequence of a monoclonal antibody derived from one species (e.g., mouse) with the constant region of an antibody derived from another species (e.g., human). The term "humanized antibody" refers to a recombinant antibody obtained by using recombinant DNA technology to replace all the amino acid sequences of the constant region and the non-CDR (Fv framework region (FR)) of the variable region of a monoclonal antibody derived from one species (e.g., mouse) with the amino acid sequences of the constant region and the non-CDR of the variable region of an antibody derived from another species (e.g., human). That is, an antibody in which the constant region is humanized is called a chimeric antibody, and an antibody in which the non-CDR amino acid sequences of both the constant region and the variable region are all humanized is called a humanized antibody. The humanization method can be carried out by referring to conventional antibody engineering techniques, so it will not be explained again here.
[0061] In another aspect of the present invention, the present invention proposes a composition. According to an example of the present invention, the composition comprises the aforementioned antibody or its antigen-binding fragment, a nucleic acid molecule, an expression vector, and recombinant cells.
[0062] The compositions according to the present invention include the aforementioned antibodies or antigen-binding fragments, nucleic acid molecules, expression vectors, and recombinant cells. In some embodiments, the compositions include combinations that are temporally and / or spatially separated, insofar as they can act together to achieve the objectives of the present invention. For example, the components of the compositions may be administered to a subject as a whole or individually to the subject. When the components of the compositions are administered to a subject individually, each component may be administered to the subject simultaneously or sequentially.
[0063] The compositions of the present invention can be administered in combination with each other or in combination with one or more other therapeutic compounds, for example, in combination with a chemotherapeutic agent. For this purpose, the compositions may further contain a chemotherapeutic agent. The antibodies or antigen-binding fragments or immune conjugates of the present disclosure may be combined with a second therapeutic agent, and examples of reagents of the second therapeutic agent include, but are not limited to, other reagents that inhibit TIGIT activity (other antibodies or antigen-binding fragments thereof, peptide inhibitors, small molecule antagonists, etc.) and / or reagents that interfere with upstream or downstream TIGIT signaling.
[0064] Typically, the antibody or its antigen-binding fragment is administered in an effective amount, i.e., an amount sufficient to achieve the desired therapeutic and / or preventive effect, for example, an amount that causes prevention or alleviation of symptoms associated with the disease being treated, and the disease being, for example, a disease associated with TIGIT. The effective amount of the composition administered to a subject depends on the type and severity of the disease, as well as individual characteristics such as general health status, age, sex, weight, and drug tolerance, and further depends on the severity and type of the disease, and a person skilled in the art can determine an appropriate dose based on these factors, etc.
[0065] In a further aspect of the present invention, the present invention proposes a drug. According to an embodiment of the present invention, the drug comprises the aforementioned antibody or its antigen-binding fragment, nucleic acid molecule, expression vector, recombinant cell, or composition, and is used to treat malignant tumors.
[0066] The drug according to the present invention contains a therapeutic agent and the aforementioned antibody or antigen-binding fragment that binds to the therapeutic agent. The method by which the antibody or antigen-binding fragment binds to the therapeutic agent is the conventional method.
[0067] In a further aspect of the present invention, the present invention proposes a kit. According to an example of the present invention, the kit comprises an antibody or antigen-binding fragment described in the first aspect of the present invention.
[0068] In a further aspect of the present invention, the present invention proposes the use of the aforementioned antibody or its antigen-binding fragment in the preparation of a kit. According to an example of the present invention, the kit is used to detect TIGIT.
[0069] The kit for detecting TIGIT in a sample according to the present invention comprises the antibody or antigen-binding fragment thereof as described above. The sample may be tissue from a patient having a disease mediated by TIGIT (particularly a patient with transplant rejection, autoimmunity, infectious disease, or cancer, more preferably a patient having at least one of the following: lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer). The kit may further include reagents for detecting conventional TIGIT, such as a coating solution.
[0070] The present invention further provides the use of the antibody or its antigen-binding fragment as described above in the preparation of reagents for detecting TIGIT in a sample. As described above, the sample may be tissue from a patient having a TIGIT-mediated disease, and this is not repeated here. The antibody or its antigen-binding fragment of the present invention has good affinity for TIGIT and can effectively detect TIGIT in a sample.
[0071] The present invention further provides the use of the antibody or its antigen-binding fragment in the preparation of drugs for the prevention and / or treatment of TIGIT-mediated diseases. Preferably, the TIGIT-mediated disease is transplant rejection, autoimmune disease, infectious disease, or cancer. More preferably, the cancer is a cancer that expresses TIGIT. Even more preferably, the cancer is at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer. Even more preferably, the infectious disease includes, but is not limited to, HIV virus infection and / or hepatitis b virus infection.
[0072] The present invention further relates to a method for preventing and / or treating TIGIT-mediated diseases (as described above), the method comprising administering to a patient an effective amount of at least one of the antibodies or antigen-binding fragments, immunoconjugates, and compositions of the present invention. The method of administration may be oral, nasal, intradermal, subcutaneous, intramuscular, intravenous, or intraperitoneal.
[0073] In relation to the present invention, "patient" or "subject" generally means mammals such as primates and / or dentans, in particular humans or mice.
[0074] Those skilled in the art can clone a DNA molecule encoding the antibody or its antigen-binding fragment of the present invention into a vector (particularly an expression vector), and further transform it into a host cell, thereby obtaining the antibody or its antigen-binding fragment by induced expression. For this reason, the present invention further provides a nucleic acid molecule encoding the antibody or its antigen-binding fragment and recombinant cells containing the nucleic acid. The nucleic acid is preferably an expression cassette obtained by genetic engineering means.
[0075] The expression vector may refer to a cloning vector or a recombinant vector, and is obtained by manipulating the nucleic acid with a commercially available vector (e.g., plasmid or viral vector). Commonly used plasmids include pSeTag2, PEE14, and pMH3.
[0076] The expression vector according to the present invention may include DNA sequences of the heavy chain variable region, light chain variable region, and / or constant region of the encoded antibody. However, two types of expression vectors can be constructed, one including the heavy chain variable region and the constant region, and the other including the light chain variable region and the constant region, to be transfected together into mammalian cells. In one preferred embodiment, the expression vector includes a promoter, a DNA sequence encoding a secretory signal peptide, and at least one antidrug gene for screening.
[0077] The recombinant cells described in the present invention may be prokaryotic host cells, eukaryotic host cells, or bacteriophages. The prokaryotic host cells may be Escherichia coli, Bacillus subtilis, Streptomyces, or Proteus mirabilis, etc. The eukaryotic host cells may include fungi such as Pichia pastrius, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Trichoderma, insect cells such as grassland rotifers, plant cells such as tobacco, and mammalian cells such as BHK cells, CHO cells, COS cells, and myeloma cells. In some embodiments, the recombinant cells described in the present invention are preferably mammalian cells, and more preferably BHK cells, CHO cells, NSO cells, or COS cells.
[0078] The nucleic acids encoding the heavy and / or light chains of the antibody of the present invention are within the scope of the present invention, and based on the amino acid sequences of the heavy and / or light chains, those skilled in the art can easily obtain the corresponding nucleotide sequences.
[0079] In this specification, antibody affinity maturation as described in the present invention refers to the normal immune function state in which a living organism exists. In humoral immunity, the average affinity of antibodies produced by re-response is higher than that of the initial immune response, and this phenomenon is called antibody affinity maturation. This functional state of the living organism is the result of long-term evolution and continuous adaptation to the external environment, and is of great importance for maintaining the organism's defense and autoimmune surveillance. The present invention is a process that uses in vitro antibody affinity maturation technology, specifically molecular biology technology, to mutate the CDR amino acids of antibodies, screen a library of mutated antibodies, and obtain antibodies with significantly improved affinity.
[0080] In this specification, H401LV2 refers to the TIGIT antibody prepared according to the present invention.
[0081] In this specification, Ka and kon have similar meanings and represent the binding constant. Kd and koff have similar meanings and represent the dissociation constant.
[0082] In this specification, Jurkat cells refer to suspension cells used to study acute T-cell leukemia, T-cell signaling, and various chemokine receptors susceptible to viral entry, particularly the immortal human T lymphocyte lineage expressed in HIV.
[0083] The embodiments of the present invention shown in the figures will be described in more detail below. The embodiments described below with reference to the drawings are illustrative and are used to interpret the present invention, and should not be understood as limitations thereto.
[0084] Note that the terms "plasmid" and "vector" used in the following examples have the same meaning and can be used interchangeably.
[0085] The parent antibody Hu4A501 used in the following examples refers to the humanized TIGIT antibody developed by this research team, and its sequence is detailed in CN109384846B.
[0086] The Tiragolumab analog used is an analogue of the anti-human TIGIT antibody Tiragolumab developed by Roche, has the same amino acid sequence as Tiragolumab, and was purchased from Hyakuei Seibutsu.
[0087] In the following examples, hIgG1 refers to the constant region of wild-type human IgG1, and the antibody administered in this form typically has ADCC (antibody-mediated cytotoxic effector) function. hIgG1LALA refers to the constant region of human IgG1 with L234A and L235A mutations, which eliminate ADCC function. hIgG4S228P refers to the constant region of human IgG4 with the S228P mutation, and wild-type IgG4 exhibits arm exchange. To eliminate this effect, the S228P mutation is often introduced through antibody engineering.
[0088] Example 1: Antibody affinity maturation To improve the suitability of antibody drug discovery and obtain high-affinity TIGIT antibodies, the inventors performed affinity maturation (completed by Jinsrui Biotechnology using FASEBA technology) on the developed humanized TIGIT antibody Hu4A501 (CN109384846B). The antigen used for affinity maturation was recombinant TIGIT extracellular domain Fc fusion protein (TIGIT-Fc) (amino acid sequence shown in SEQ ID NO: 9). The heavy chain variable region and light chain variable region of the obtained matured TIGIT antibody H401LV2 are shown in SEQ ID NO: 7 and 8. QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGTLLTVSS(SEQ ID NO: 7), DIVMTQSPPSSMSTSVGDRVTITCRASQDVFNQVAWYQQKPGKSPKLLIYSASFRYTGVPDRFSGSGSGTDFTFTISSVQAEDFATYYCQQHYSTPLTFGAGTKLELK(SEQ ID NO:8), MMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFLEVLELEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 9).
[0089] Example 2: Antibody affinity detection
[0090] The Biacore method is a recognized detection method for objectively detecting protein affinity and dynamics, and the Biacore T200 will be used to analyze the characterization of the affinity and binding dynamics of the TIGIT antibody of the present invention.
[0091] The TIGIT extracellular Fc fusion protein (TIGIT-Fc) was covalently fused to a CM5 (GE) chip using a standard amino coupling method. Next, a series of concentration gradients of TIGIT antibodies diluted in PBS buffer were injected in each cycle, followed by regeneration with 10 mM NaOH solution. Antigen-antibody binding dynamics were tracked for 3 minutes, and dissociation dynamics for 10 minutes. Data obtained using a 1:1 (Langmuir) binding model were analyzed using GE's BIAevaluation software, and the Ka(kon), Kd(koff), and KD values measured in this manner are shown in Table 1 below.
[0092] [Table 1] Note: Ka represents the binding constant (a larger value indicates stronger affinity), Kd represents the dissociation constant (a smaller value indicates stronger affinity) and reflects the degree of affinity of the compound to its target, and KD represents Kd / Ka and is the affinity constant.
[0093] Example 3: ELISA binding experiment of TIGIT antibody
[0094] According to an embodiment of the present invention, the binding characteristics of a TIGIT antibody are detected using an ELISA experiment. A TIGIT extracellular region His tag fusion protein is coated onto a 96-well plate, and after adding the antibody, the binding characteristics of the antibody and the TIGIT protein are determined based on the signal intensity. The experimental steps are specifically as follows. 1. Antibody preparation The pcDNA3.4 vectors (synthesized by Nanjing Jinsrui) contain the nucleotide sequences of the heavy and light chains of the above antibodies: Hu4A501 light chain Hu4A501-hK (amino acid sequence shown in SEQ ID NO:17), Hu4A501 heavy chain H401LV2-hIgG1 (amino acid sequence shown in SEQ ID NO:18), H401LV2 light chain H401LV2-hK (amino acid sequence shown in SEQ ID NO:19), H401LV2 heavy chain H401LV2-hIgG1 (amino acid sequence shown in SEQ ID NO:20), H401LV2-hIgG1LALA (amino acid sequence shown in SEQ ID NO:21), and H401LV2-hIgG4S228P (amino acid sequence shown in SEQ ID Antibodies were prepared by transiently transfecting ExpiCHO-S cells (Gibco, item A29127) with the agent shown in NO:22. DIVMTQSPSSMSSTSVGDRVTITCRASQDVFTAVAWYQQKPGKSPKLLIYSASFRYTGVPDRFSGSGSGTDFTFTISSVQAEDFATYYCQQHYSTPLTFGAGTKLELKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:17) QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:18) DIVMTQSPSSMSTSVGDRVTITCRASQDVFNQVAWYQQKPGKSPKLLIYSASFRYTGVPDRFSGSGSGTDFTFTISSVQAEDFATYYCQQHYSTPLTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:19) QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:20) QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:21) QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQG TLLTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC PPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK(SEQ ID NO:22)
[0095] The day before transfection, ExpiCHO-S cells were placed at a cell density of (3-4) × 10 6 The solution was adjusted to / mL and cultured overnight with vibrations at 37°C, 8% CO2, and 95 rpm. On the day of transfection, 7 × 10⁶ cells were placed. 6 ~1 × 10 7 When the cells have grown to 6 × 10¹ / mL and the viability exceeds 95%, prepare for transfection and use fresh, preheated ExpiCHO medium (Gibco, item A2910002) to transfect the cells. 6Diluted to 1 / mL, the pcDNA3.4 plasmid (1:1 heavy-to-light chain plasmid ratio) carrying the heavy and light chains described above was transfected into ExpiCHO-S cells with ExpiFectamine CHO transfection reagent (Gibco, item A29129), and the cells were cultured with vibrations at 37°C, 8% CO2, and 95 rpm. 18-22 hours after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were homogeneously mixed, and immediately after, the transfected cells were added and homogeneously mixed. The cells were then cultured with vibrations at 32°C, 5% CO2, and 95 rpm. On day 5 after transfection, 8 mL of ExpiCHO Feed was added to the cells, homogeneously mixed, and culture was continued. Changes in cell number and cell viability were observed daily, and cells were harvested by centrifugation after the cell viability fell below 80% or after 10-14 days of culture. The expression supernatant was filtered through a 0.45 μm filter, and the Fc domain-containing antibody was captured from the expression supernatant using a Mabselect prism Aprotein A affinity chromatography column (purchased from Suzhou Nawei). After equilibrating the chromatography column with pH 7.2 phosphate buffer, the supernatant was passed through the affinity chromatography column and eluted with elution buffer (100 mM citrate, pH 2.7). Finally, the supernatant was concentrated and replaced with PBS buffer. The purified antibody was identified as having a purity of over 95% by SDS-PAGE, and from these results, it was determined that the antibody described above was ultimately obtained.
[0096] 2. Detection of TIGIT antibody binding characteristics by ELISA experiment
[0097] 1. Human and cynomolgus monkey TIGIT-His tag fusion proteins (purchased from Acro) were diluted to 2 μg / ml with PBS buffer, added to a 96-well plate at a volume of 100 μL / well, and left to stand overnight at 4°C. 2. Aspirate and remove the PBS buffer from the 96-well plate in Step 1, wash the plate six times with PBST buffer (pH 7.2, containing 0.1% Tween20 by total volume), then incubate in 200 μl / well of PBS buffer (containing 10% volume of BSA (bovine serum albumin)) at 37°C for 2 hours to block. 3. Remove the PBS buffer from step 2, wash the plate six times with PBST buffer, then add 100 μl / well of PBST buffer (containing 0.05% volume of BSA) to dilute the target TIGIT antibody to 10000, 2000, 400, 80, 16, 3.2, 0.64, and 0.128 ng / ml, and incubate at 37°C for 1 hour. 4. After removing the buffer from step 3 and washing the plate six times with PBST, the HRP (horseradish peroxidase)-labeled human IgG antibody (secondary antibody, purchased from Jacksonlab) was diluted in PBST buffer (containing 0.05% volume of BSA) at a rate of 100 μl / well and incubated at 37°C for 1 hour. 5. Wash the 96-well plate from step 4 six times with PBST buffer, add 80 μl / well of TMB (tetramethylbenzidine), incubate at room temperature for 3 minutes, then add 80 μl / well of 4M sulfuric acid to stop the reaction. 6. The absorbance of the 96-well plate at 450 mm in step 5 was read using a microplate reader.
[0098] The results are shown in Figure 1, and it was found that the TIGIT antibodies H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) prepared in this invention can bind to the TIGIT protein, and that the binding is stronger than that of the parent antibody Hu4A501 and the Tiragolumab analog (purchased from Hyakuei Seibutsu).
[0099] Example 4: ELISA rejection experiment of TIGIT antibody
[0100] According to an embodiment of the present invention, the binding characteristics of a TIGIT antibody are detected using an ELISA experiment. A TIGIT extracellular domain His tag fusion protein is coated onto a 96-well plate, and after adding the antibody and CD155-Biotin, the antibody's ability to inhibit TIGIT / CD155 binding is determined based on the signal intensity. The specific steps are as follows. 1. Human and cynomolgus monkey TIGIT-His tag fusion proteins (purchased from Acro) were diluted to 2 μg / ml with PBS buffer, added to a 96-well plate at a volume of 100 μL / well, and left to stand overnight at 4°C. 2. Aspirate and remove the PBS buffer from the 96-well plate in Step 1, wash the plate six times with PBST buffer (pH 7.2, containing 0.1% Tween20 by total volume), then incubate 200 μl / well of PBS buffer / (containing 10% volume of BSA (bovine serum albumin)) with 10% BSA at 37°C for 2 hours to block. 3. Remove the PBS buffer and blocking solution from step 2, wash the plate six times with PBST buffer, then dilute the TIGIT antibody to an appropriate concentration by adding 100 μl / well of PBST buffer (containing 0.05% volume BSA) / 0.05% BSA, and incubate at 37°C for 1 hour. 4. Remove the buffer from step 3 of the reaction system, wash the plate 6 times with PBST, then dilute the HRP (horseradish peroxidase)-labeled anti-human IgG secondary antibody (secondary antibody, purchased from Jacksonlab) with PBST buffer (containing 0.05% volume of BSA) at a rate of 100 μl / well, and incubate at 37°C for 1 hour. 5. The 96-well plate from step 4 was washed six times with PBST buffer, 80 μl / well of TMB (tetramethylbenzidine) was added, and the mixture was incubated at room temperature for 3 minutes. Then, 80 μl / well of 4M sulfuric acid was added to stop the reaction. 6. The absorbance of the 96-well plate at 450 mm in step 5 was read using a microplate reader.
[0101] The results are shown in Figure 2, and it was found that the TIGIT antibodies H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) prepared in this invention were able to inhibit the binding of TIGIT / CD155, and that their inhibitory ability was not weaker than that of tiragolumab analogs (purchased from Hyakuei Seibutsu).
[0102] Example 5: TIGIT antibody-conjugated 293T-TIGIT experiment
[0103] According to an embodiment of the present invention, the binding characteristics of the TIGIT antibody are detected using a flow cetocemetry experiment, the TIGIT protein (annotated as 293T-TIGIT) is overexpressed in HEK293T cells (ATCC number CRL-3216), and after adding an antibody (it is necessary to supplement the antibody added here), the binding characteristics of the chimeric antibody and TIGIT are determined based on the signal intensity. The specific steps are as follows. 1. HEK293T cells 5 × 10 5 Cells were added to a 6-well plate at a rate of one cell per well, and cultured overnight in DMEM medium without the biantibody. 2. Before transfection, the medium was discarded and 1 ml of fresh, double antibody-free DMEM medium was added. The pLVX-EF1a-TIGIT-IRES-puro vector (with the TIGIT protein sequence (SEQ ID NO: 11) inserted between the enzymatic cleavage sites EcoRI and BamHI of the pLVX-EF1a-IRES-puro vector) was added to 200 μl of serum-free DMEM medium in a 2:1:1 ratio with pMD2G and psPAX2 vectors (a total of 3 μg of the three vectors). MRWCLLLIWAQGLRQAPLASGMMTGTIETTGNISAEKGGSIILQCHLSSTTAQVTQVNWEQQDQLLAICNADLGWHISPSFKDRVAPGPGLGLTLQSLTVNDTGEYFCIYHTYPDGTYTGRIFL EVLESSVAEHGARFQIPLLGAMAATLVVICTAVIVVVALTRKKKALRIHSVEGDLRRKSAGQEEWSPSPSPPGSCVQAEAAPAGLCGEQRGEDCAELHDYFNVLSYRSLGNCSFFTETG(SEQ ID NO:11). 3. 12 μg of polyetherimide (PEI, Polysciences Inc.) was added to the culture medium from step 2. After homogeneous mixing, it was allowed to stand for 16 minutes, and then all the liquid was added to a 6-well plate containing HEK293T cells and cultured for 6 hours. The culture medium in the 4.6-well plate was discarded, and fresh complete DMEM medium was added for incubation. 48 hours after transfection, the supernatant of the cell culture medium was collected and filtered through a 0.45 μm filter (purchased from Millipore) to obtain the viral supernatant. 5. All of the viral supernatant from step 4 is 1 × 10 4 In addition to a 6-well plate containing HEK293T cells, polyblen (purchased from Sigma) at a final concentration of 4 μg / ml was added and the cells were cultured for 12 hours. 6. The supernatant from step 5 was completely removed, and fresh complete DMEM medium was added. The cultured cells were 293T-TIGIT cells. 7. 2 × 10⁶ cells of 293T-TIGIT cells in PBS. 6 The solution was diluted to 1 / ml and added to a 1.5 ml EP tube at a volume of 100 μl / tube. 10 μl / tube of mouse serum was then added, and the mixture was blocked at 4°C for 30 minutes. 8. Add TIGIT antibodies at different concentration gradients (maximum 8 μg / ml, 5-fold gradient dilution, 8 gradients) to the EP tubes from Step 7 and incubate at 4°C for 30 minutes. 9. Add 1 ml of PBS to the EP tube from Step 8, centrifuge at 3500 rpm at 4°C for 5 min, completely remove the supernatant, and wash once more with PBS. After centrifugation, completely remove the supernatant, resuspend the cells in 100 μl / tube of PBS, add 1 μl / tube of Alexa-647 labeled mouse anti-human Fc antibody (secondary antibody, purchased from Jacksonlab), and incubate in the dark for 30 min at 4°C. 10. Wash the cells from step 9 with PBS, centrifuge, and completely remove the supernatant. Resuspend the cells in 200 μl / tube of PBS buffer and detect by flow cytometry.
[0104] The results are shown in Figure 3, and it was found that the TIGIT antibodies H401LV2 (H401LV2-hlgG1, H401LV2-hlgG1LALA, H401LV2-hlgG4S228P) of the present invention can bind to 293T-TIGIT.
[0105] Example 6: Detection of TIGIT antibody blocking ability
[0106] The TIGIT antibody inhibits the binding of TIGIT to its ligand CD155 by binding to the extracellular domain of TIGIT. In the examples of the present invention, the inhibitory effect of the TIGIT antibody on the binding of CD155 to 293T-TIGIT was detected by flow cetometry experiment, and the specific steps are as follows. 1. Prepare 293T-TIGIT cells (same as in Example 5) in PBS, then divide into 2 × 10⁻¹⁶ cells. 6 The solution was diluted to 1 / ml and added to a 1.5 ml EP tube at a volume of 100 μl / tube. 10 μl / tube of mouse serum was then added to the tube, and the mixture was blocked at 4°C for 30 minutes. 2. Add the TIGIT antibody and CD155-mIgG2a-Fc (purchased from Acro), diluted to a maximum of 200 μg / ml with a 5-fold gradient (a total of 10 gradient dilutions), to the EP tubes from Step 1, and incubate at 4°C for 30 minutes. 3. Add APC-labeled goat anti-mouse IgG2a secondary antibody (purchased from Biolegend) at 0.1 μg / tube to the EP tube from Step 2, and incubate at 4°C for 30 min. Wash twice with PBS, centrifuge, and then completely remove the supernatant. Resuspend the cells with 200 μl / tube of PBS, and perform detection with a flow cytometer.
[0107] The results are shown in Figure 4. It was found that all of the TIGIT antibodies H401LV2 (H401LV2-hIgG1, H401LV2-hIgG1LALA, H401LV2-hIgG4S228P) of the present invention with different constant regions can block the binding between CD155-mIgG2a and 293T-TIGIT, and the blocking capability is not weaker than that of the Tiragolumab analog (purchased from Bioxcell).
[0108] Example 7: Experiment on promoting Jurkat T cell activation by TIGIT antibody
[0109] Jurkat cells and U-937 tumor cells were co-incubated, CD3 antibody and TIGIT antibody were added, and the content of IL-2 in the supernatant was detected. The activation effect on Jurkat cells was determined based on the intensity of the IL-2 signal after antibody addition, and the specific operation steps are as follows. 1. Dilute OKT3 antibody (purchased from Biolegend) to 0.2 μg / ml with PBS, add to a 96-well plate, allow to react overnight, and discard the supernatant. 2. Dilute Jurkat cells to 1×10 6 / ml with complete 1640 medium, add to the 96-well plate at a volume of 100 μl / well, dilute U-937 cells to 1.25×10 6 / ml with complete 1640 medium, add to the 96-well plate at a volume of 80 μl / well, dilute TIGIT antibody to 100 μg / ml with complete 1640 medium, and add to the 96-well plate at 20 μl / well. Culture for 24 h in an incubator containing 5% CO2 at 37°C, and detect IL-2 in the supernatant using a CBA kit (purchased from BD).
[0110] The results are shown in Figure 5, and the affinity-matured TIGIT antibody H401LV2-hlgG1LALA of the present invention is superior to that of the parent antibody Hu4A501-hlgG1LALA in its ability to promote Jurkat T cell activation.
[0111] Example 8: TIGIT antibody-conjugated CHO-K1-TIGIT experiment
[0112] In the embodiment of the present invention, the binding characteristics of the TIGIT antibody were detected using flow cetocemetry experiments, and the TIGIT protein (annotated as CHO-K1-TIGIT) was overexpressed in CHO-K1 cells (ATCC number CCL-61). The binding characteristics of the chimeric antibody and TIGIT were determined based on the intensity of the signal after antibody entrainment. 1. Antibody preparation: The pcDNA3.4 vectors (synthesized by Nanjing Jinsrui) contain the nucleotide sequences of the heavy and light chains of the above antibodies: 4.1D3 light chain 4.1D3-mK (amino acid sequence shown in SEQ ID NO:10), 4.1D3 heavy chain 4.1D3-mIgG2a (amino acid sequence shown in SEQ ID NO:11), 22G2 light chain 22G2-mK (amino acid sequence shown in SEQ ID NO:12), 22G2 heavy chain 22G2-mIgG2a (amino acid sequence shown in SEQ ID NO:13), H401LV2 light chain H401LV2-mK (amino acid sequence shown in SEQ ID NO:14), H401LV2 heavy chain H401LV2-mIgG2a (amino acid sequence shown in SEQ ID Antibodies were prepared by transiently transfecting ExpiCHO-S cells (Gibco, item A29127) with the agent shown in NO:15. DIVMTQSPDSLAVSLGERATINCKSSQTVLYSSNNKKYLAWYQQKPGQPPNLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPFTFGPGTKVEI KRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(SEQ ID NO:10), EVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGKTYYRFKWYSDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAVFYCTRESTTYDLLAGPFDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK(SEQ ID NO:11)、 EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLFTFGPGTKVDIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(SEQ ID NO:12)、 QVQLQESGPGLVKPSETLSLTCTVSGGSVSSGIYYWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYYVSGNYYNVDYYFFGVDVWGQGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK(SEQ ID NO:13)。 DIVMTQSPSSMSTSVGDRVTITCRASQDVFNQVAWYQQKPGKSPKLLIYSASFRYTGVPDRFSGSGSGTDFTFTISSVQAEDFATYYCQQHYSTPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(SEQ ID NO:14) QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGT LLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC PPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTIS KPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK(SEQ ID NO:15)
[0113] The day before transfection, ExpiCHO-S cells were placed at a cell density of (3-4) × 10 6 The solution was adjusted to / mL and cultured overnight with vibrations at 37°C, 8% CO2, and 95 rpm. On the day of transfection, 7 × 10⁶ cells were placed. 6 ~1 × 10 7 When the cells have grown to 6 × 10¹ / mL and the viability exceeds 95%, prepare for transfection and infuse the cells in fresh, preheated ExpiCHO medium (Gibco, item A2910002) in 6 × 10¹⁶ cells. 6Diluted to 1 / mL, the pcDNA3.4 plasmid (1:1 heavy-to-light chain plasmid ratio) carrying the heavy and light chains described above was transfected into ExpiCHO-S cells with ExpiFectamine CHO transfection reagent (Gibco, item A29129), and the cells were cultured with vibrations at 37°C, 8% CO2, and 95 rpm. 18-22 hours after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were homogeneously mixed, and immediately after, the transfected cells were added and homogeneously mixed. The cells were then cultured with vibrations at 32°C, 5% CO2, and 95 rpm. On day 5 after transfection, 8 mL of ExpiCHO Feed was added to the cells, homogeneously mixed, and culture was continued. Changes in cell number and cell viability were observed daily, and cells were harvested by centrifugation after the cell viability fell below 80% or after 10-14 days of culture. The expression supernatant was filtered through a 0.45 μm filter, and the Fc domain-containing antibody was captured from the expression supernatant using a Mabselect prism Aprotein A affinity chromatography column (purchased from Suzhou Nawei). After equilibrating the chromatography column with pH 7.2 phosphate buffer, the supernatant was passed through the affinity chromatography column and eluted with elution buffer (100 mM citrate, pH 2.7). Finally, the supernatant was concentrated and replaced with PBS buffer. The purified antibody was identified as having a purity of over 95% by SDS-PAGE, and from these results, it was determined that the antibody described above was ultimately obtained.
[0114] 2. Detection of binding characteristics of chimeric antibodies and TIGIT by flow cetocemetry. 1. HEK293T cells 5 × 10 5 Cells were added to a 6-well plate at the specified cell / well level and cultured overnight in DMEM medium without the biantibody. 2. Before transfection, the culture medium was discarded and 1 ml of fresh, double antibody-free DMEM medium was added. The pLVX-EF1a-TIGIT-IRES-puro vector (with the TIGIT protein inserted between the enzymatic cleavage sites EcoRI and BamHI of the pLVX-EF1a-IRES-puro vector) was inserted, and pMD2G and psPAX2 vectors (a total of 3 μg of the three vectors) were added to 200 μl of serum-free DMEM medium in a 2:1:1 ratio. 3. Add 12 μg of polyetherimide (PEI, Polysciences Inc.) to the culture medium from step 2, mix uniformly, and let stand for 16 minutes. Then, add the entire liquid to a 6-well plate on which CHO-K1 cells were laid. 4. The 6-well plates from step 3 were cultured for 6 hours, the culture medium was discarded, and fresh complete DMEM medium was added for further culture. 5. 48 hours after transfection, the supernatant of the cell culture was collected and filtered through a 0.45 μm filter (purchased from Millipore). The obtained filtrate was the viral supernatant. 6. Collect all of the viral supernatant in 1 x 10⁻¹⁶ units. 4 In addition to a 6-well plate containing 293T cells, polyblen (purchased from Sigma) at a final concentration of 4 μg / ml was added and cultured for 12 hours. 7. Completely remove the supernatant, add fresh complete DMEM medium, and culture the cells. The cultured cells are CHO-K1-TIGIT cells. 8. CHO-K1-TIGIT cells are incubated in PBS for 2 × 10⁻¹⁶ cells. 6 The solution was diluted to 1 / ml and added to a 1.5 ml EP tube at a volume of 100 μl / tube. 10 μl / tube of mouse serum was then added to the tube, and the mixture was blocked in a refrigerator at 4°C for 30 minutes. 9. Add TIGIT antibodies of different concentrations to the EP tubes from step 8 and incubate in a refrigerator at 4°C for 30 minutes. Add 1 ml of PBS to the EP tubes and centrifuge at 3500 rpm at 4°C for 5 minutes, completely removing the supernatant. 10. Resuspend the cells again using PBS, centrifuge and completely remove the supernatant, resuspend the cells in 100 μl / tube of PBS, add 1 μl / tube of Alexa-647-labeled mouse anti-human Fc antibody (secondary antibody, purchased from Jacksonlab), and incubate at 4°C for 30 minutes in the dark. Wash twice with PBS, centrifuge, and completely remove the supernatant. The cells were resuspended in 11,200 μl / tube of PBS and then detected using a flow cytometer.
[0115] The results are shown in Figure 6, confirming that the TIGIT antibody H401LV2-mlgG2a of the present invention can bind to CHO-K1-TIGIT and that its binding ability is 4.1D3, which is superior to that of the 22G2 antibody.
[0116] Example 9: Detection of TIGIT antibody blocking ability
[0117] The TIGIT antibody inhibits the binding of TIGIT to its ligand CD155 by binding to the extracellular domain of TIGIT. In this invention, the inhibitory effect of the TIGIT antibody on the binding of CD155 to CHO-K1-TIGIT was detected by flow cetometry experiments, and the specific steps are as follows. 1. Prepare 2 × 10⁶ CHO-K1-TIGIT cells (same as in Example 8) in PBS. 6 The solution was diluted to 1 / ml and added to a 1.5 ml EP tube at a volume of 100 μl / tube. 10 μl / tube of mouse serum was then added to the tube, and the mixture was blocked for 30 minutes at 4°C. 2. TIGIT antibodies (30, 10, 3, 1, 0.1, 0.01, 0.001 μg / ml) and CD155-mIgG2a-Fc (purchased from Acro) were added and incubated at 4°C for 30 minutes. 0.1 μg / ampoule of APC-labeled sheep anti-mouse IgG2a (secondary antibody, purchased from Biolegend) was added and incubated at 4°C for 30 minutes. 3. The cells were washed twice with PBS, centrifuged, and the supernatant was completely removed. The cells were resuspended in 200 μl / tube of PBS and finally detected by flow cytometry.
[0118] The results are shown in Figure 7, confirming that the antibody H401LV2-mlgG2a of the present invention can inhibit the binding of CD155 to CHO-K1-TIGIT, and that its inhibitory ability is stronger than that of the 4.1D3 antibody.
[0119] Example 10: Effects of H401LV2 antibody on mouse cancer
[0120] In vivo efficacy experiments are used to detect the effect of the affinity-matured TIGIT antibody H401LV2 on the anti-cancer function of hTIGIT transgenic mice. The specific steps are as follows:
[0121] 1. Antibody preparation Antibodies were prepared by transiently transfecting ExpiCHO-S cells (Gibco, item A29127) with pcDNA3.4 vectors (synthesized by Nanjing Jinsui) containing the nucleotide sequences of the heavy and light chains of the above antibodies: H401LV2-mK (the H401LV2 light chain, whose amino acid sequence is shown in SEQ ID NO: 14), H401LV2-mIgG2a (the H401LV2 heavy chain, whose amino acid sequence is shown in SEQ ID NO: 15), and H401LV2-mIgG2aD265A (the amino acid sequence is shown in SEQ ID NO: 16). QVQLQESGPGLVKPSQTLSLTCTVTGSSITSDYAWNWIRQFPGKKLEWMGYITYSGRTTYNPSLKSRITISRDTSKNQFSLKLSSVTAADTATYYCARWGLLRRYFDYWGQGT LLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPC PPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTIS KPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK(SEQ ID NO:16)
[0122] The day before transfection, ExpiCHO-S cells were placed at a cell density of (3-4) × 10 6 The solution was adjusted to / mL and cultured overnight with vibrations at 37°C, 8% CO2, and 95 rpm. On the day of transfection, 7 × 10⁶ cells were placed. 6 ~1 × 10 7 When the cells have grown to 6 × 10¹ / mL and the viability exceeds 95%, prepare for transfection and infuse the cells in fresh, preheated ExpiCHO medium (Gibco, item A2910002) in 6 × 10¹⁶ cells. 6Diluted to 1 / mL, the pcDNA3.4 plasmid (1:1 heavy-to-light chain plasmid ratio) carrying the heavy and light chains described above was transfected into ExpiCHO-S cells with ExpiFectamine CHO transfection reagent (Gibco, item A29129), and the cells were cultured with vibrations at 37°C, 8% CO2, and 95 rpm. 18-22 hours after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were homogeneously mixed, and immediately after, the transfected cells were added and homogeneously mixed. The cells were then cultured with vibrations at 32°C, 5% CO2, and 95 rpm. On day 5 after transfection, 8 mL of ExpiCHO Feed was added to the cells, homogeneously mixed, and culture was continued. Changes in cell number and cell viability were observed daily, and cells were harvested by centrifugation after the cell viability fell below 80% or after 10-14 days of culture. The expression supernatant was filtered through a 0.45 μm filter, and the Fc domain-containing antibody was captured from the expression supernatant using a Mabselect prism Aprotein A affinity chromatography column (purchased from Suzhou Nawei). After equilibrating the chromatography column with pH 7.2 phosphate buffer, the supernatant was passed through the affinity chromatography column and eluted with elution buffer (100 mM citrate, pH 2.7). Finally, the supernatant was concentrated and replaced with PBS buffer. The purified antibody was identified as having a purity of over 95% by SDS-PAGE, and from these results, it was determined that the antibody described above was ultimately obtained. 2. On day 0 of detecting the anti-cancer function of hTIGIT transgenic mice using H401LV2, hTIGIT tumor-carrying mice (purchased from southern type animals) were given 2 × 10⁶ mice per mouse. 5 1 MC38 cells (Figure 8), or 1 × 10⁶ cells per mouse 6 Individual LLC cells (Figure 9) are injected, and the mice are randomly divided into groups. 2. On days 4, 7, 10, and 13, the affinity matured antibody is intraperitoneally injected into the mice at a dose of 250 μg per mouse. 3. Tumor volume was measured once every three days after the above antibody injection.
[0123] The results are shown in Figure 8, indicating that H401LV2-mIgG2a with ADCC effector function showed better therapeutic efficacy in the MC38 colorectal cancer model, and as shown in Figure 9, H401LV2-mIgG2aD265A without ADCC effector function showed better therapeutic efficacy in the LLC lung cancer model.
[0124] As can be seen from the experimental results above, the high-affinity antibody obtained in this invention can bind to TIGIT. By inhibiting the interaction between TIGIT and CD155, it activates the immune cell anti-cancer mechanism.
[0125] Furthermore, terms such as "first" and "second" are merely descriptive and cannot be considered to indicate or implicitly suggest relative importance, or to implicitly indicate a number of technical features. Thus, features designated as "first" or "second" can be explicitly or implicitly indicated to include one or more such features. Moreover, in the description of this invention, unless otherwise specified, "multiple" means at least two, for example, two, three, etc.
[0126] In this specification, any reference to terms such as “one embodiment,” “several embodiments,” “example,” “specific example,” or “several examples” means that a particular feature, structure, material, or property described with reference to such embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the general expressions of the above terms do not necessarily apply to the same embodiment or example. In addition, any particular feature, structure, material, or property described may be incorporated in an appropriate manner in any one or more embodiments or examples. Furthermore, those skilled in the art can combine and combine the various embodiments or examples and the features relating to the various embodiments or examples described herein without contradiction.
[0127] Although preferred embodiments of the present invention have been described in detail above, the present invention is not limited thereto. Within the scope of the technical concept of the present invention, the technical solutions of the present invention can be modified in several simple ways, including combining each technical feature in other appropriate ways, and these simple modifications and combinations should also be considered as part of the disclosure of the present invention and all fall within the scope of protection of the present invention.
Claims
1. An antibody or antigen-binding fragment capable of specifically recognizing TIGIT, An antibody or its antigen-binding fragment, comprising a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
8.
2. The antibody or its antigen-binding fragment according to claim 1, characterized in that the antibody is a humanized antibody.
3. The antibody or antigen-binding fragment according to claim 1, wherein the antibody or antigen-binding fragment comprises a heavy chain framework region sequence and a light chain framework region sequence, and at least a portion of at least one of the heavy chain framework region sequence and the light chain framework region sequence is derived from at least one of a mouse-derived antibody, a human-derived antibody, a primate-derived antibody, or a variant thereof.
4. The antibody or antigen-binding fragment according to claim 1, wherein the antibody or antigen-binding fragment contains at least one of a heavy chain constant region and a light chain constant region, and at least a portion of the heavy chain constant region and at least one of the light chain constant region is derived from at least one of a human antibody, a primate antibody, a mouse antibody or a variant thereof.
5. The antibody or antigen-binding fragment according to claim 4, wherein the antibody or antigen-binding fragment comprises a heavy chain constant region and a light chain constant region, and both the light chain constant region and the heavy chain constant region are derived from a mouse-derived IgG1 antibody, IgG2a antibody or a variant thereof, or a human-derived IgG1 antibody, IgG2 antibody, IgG3 antibody, IgG4 antibody or a variant thereof.
6. The antibody or antigen-binding fragment according to claim 1, characterized in that the antibody or antigen-binding fragment is at least one of a single-chain antibody, a multimer antibody, a CDR-transplant antibody, a Fab antibody, or an Fv antibody.
7. A nucleic acid molecule characterized by encoding the antibody or its antigen-binding fragment as described in claim 1.
8. An expression vector characterized by supporting the nucleic acid molecule described in claim 7.
9. A method for preparing an antibody or its antigen-binding fragment according to any one of claims 1 to 2 or 5 to 6, The steps of introducing the expression vector described in claim 8 into cells, A method characterized by comprising the step of culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or its antigen-binding fragment.
10. The method according to claim 9, characterized in that the cells are eukaryotic cells.
11. Recombinant cells characterized by expressing an antibody or antigen-binding fragment according to any one of claims 1 to 6, or carrying a nucleic acid molecule according to claim 7 or an expression vector according to claim 8.
12. A composition comprising an antibody or antigen-binding fragment according to any one of claims 1 to 6, a nucleic acid molecule according to claim 7, or an expression vector according to claim 8.
13. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1-2 or 5-6, a nucleic acid molecule according to claim 7, or an expression vector according to claim 8 in the preparation of a drug for treating or preventing malignant tumors.
14. The use according to claim 13, characterized in that the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
15. A drug for treating malignant tumors, comprising an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, a nucleic acid molecule according to claim 7, or an expression vector according to claim 8.
16. The drug according to claim 15, characterized in that the malignant tumor includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, kidney cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
17. Use of the antibody or antigen-binding fragment according to any one of claims 1 to 2 or 5 to 6 in the preparation of a kit for detecting TIGIT.
18. A kit characterized by comprising an antibody or antigen-binding fragment according to any one of claims 1 to 6.
Citation Information
Patent Citations
Antibody or antigen binding fragment capable of being bonded with TIGIT and use thereof
CN109384846A
